Despite these recent developments the identification of novel substances selectively inhibiting glucagon action is still of great therapeutic interest due to the possibility of direct interference with the crucial pathophysiological mechanisms of hyperglycemia in diabetes. This evidence concerns the gene GCG and diabetes mellitus.